The potential effect of multiple pulse mode Q-switched neodymium-doped yttrium aluminum garnet laser combined with tranexamic acid on dermal remodeling in melasma treatment: a case report
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Oral tranexamic acid (TXA) is a proven first-line approach for the treatment of recalcitrant melasma. A novel multi-pulse width 1,064 nm Q-switched Nd:YAG (Q-NDY) laser coupled with the micropulse mode (L-NDY, Genesis technique) has shown promise in pigment removal. In this study five female patients were randomly assigned to receive the combination treatment of Q-NDY + L-NDY + TXA (8 sessions, 3 subjects, Group A) or Q-NDY + L-NDY only (10 sessions, 2 subjects, Group B). At the final assessment, both groups showed extremely significant clearance of pigment as observed through the melasma area and severity index scores, although Group A was better than Group B. The combination of TXA, Q-NDY, and L-NDY for pigment removal and restoration of dermal health is a promising minimally invasive approach for melasma treatment. The good results in the laser-only group holds equal promise for those patients unable to take oral TXA.
Abstract
Oral tranexamic acid (TXA) is a proven first-line approach for the treatment of recalcitrant melasma. A novel multi-pulse width 1,064 nm Q-switched Nd:YAG (Q-NDY) laser coupled with the micropulse mode (L-NDY, Genesis technique) has shown promise in pigment removal. In this study five female patients were randomly assigned to receive the combination treatment of Q-NDY + L-NDY + TXA (8 sessions, 3 subjects, Group A) or Q-NDY + L-NDY only (10 sessions, 2 subjects, Group B). At the final assessment, both groups showed extremely significant clearance of pigment as observed through the melasma area and severity index scores, although Group A was better than Group B. The combination of TXA, Q-NDY, and L-NDY for pigment removal and restoration of dermal health is a promising minimally invasive approach for melasma treatment. The good results in the laser-only group holds equal promise for those patients unable to take oral TXA.